0001209191-22-023845.txt : 20220408 0001209191-22-023845.hdr.sgml : 20220408 20220408160949 ACCESSION NUMBER: 0001209191-22-023845 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220406 FILED AS OF DATE: 20220408 DATE AS OF CHANGE: 20220408 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hoelscher Paul W. CENTRAL INDEX KEY: 0001611468 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 22817083 MAIL ADDRESS: STREET 1: 520 LAKE COOK ROAD, SUITE 520 STREET 2: C/O HORIZON PHARMA, INC. CITY: DEERFIELD STATE: IL ZIP: 60062 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-06 0 0001492426 Horizon Therapeutics Public Ltd Co HZNP 0001611468 Hoelscher Paul W. C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN?S GREEN DUBLIN L2 D02 E2X4 IRELAND 0 1 0 0 EVP, CFO Ordinary Shares 2022-04-06 4 M 0 30275 15.96 A 31324 D Ordinary Shares 2022-04-06 4 M 0 185060 22.14 A 216384 D Ordinary Shares 2022-04-06 4 S 0 215335 110.009 D 1049 D Ordinary Shares 2022-04-06 4 S 0 91710 110.0101 D 66673 I By LLC Ordinary Shares 72789 I By Trust Stock Option (Right to Buy) 15.96 2022-04-06 4 M 0 30275 0.00 D 2024-06-26 Ordinary Shares 30275 0 D Stock Option (Right to Buy) 22.14 2022-04-06 4 M 0 185060 0.00 D 2025-03-22 Ordinary Shares 185060 86424 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC. The option is fully vested and exercisable. /s/ Miles W. McHugh, Attorney-in-Fact 2022-04-08